Kazia Therapeutics (KZIA) Cash & Equivalents (2009 - 2025)

Kazia Therapeutics (KZIA) has 14 years of Cash & Equivalents data on file, last reported at $45.6 million in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 2175.82% year-over-year to $45.6 million; the TTM figure through Dec 2025 stood at $45.6 million (up 2175.82% YoY), while the FY2025 annual figure was $2.8 million, up 154.81% from the prior year.
• Cash & Equivalents improved to $45.6 million in Q4 2025, from $2.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $45.6 million in Q4 2025 and bottomed at $1.1 million in Q2 2024.
• A 5-year average of $9.6 million and a median of $2.9 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 75.18% — and 2025, when it jumped 2175.82%.
• Year by year, Cash & Equivalents stood at $21.2 million in 2021, then plunged by 86.42% to $2.9 million in 2022, then declined by 19.6% to $2.3 million in 2023, then retreated by 13.59% to $2.0 million in 2024, then jumped by 2175.82% to $45.6 million in 2025.
• The last three Cash & Equivalents figures came in at $45.6 million (Q4 2025), $2.8 million (Q2 2025), and $2.0 million (Q4 2024), per Business Quant data.

Peer Comparison